



National
Library
of Medicine

PubM d Nuclotide Prot in Genome Structure PopSet Taxonomy OMIM Bi

Search



for

Limits

Preview/Index

History



Clear

Clipboard

Details

About Entrez

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

PubMed Services

Journal Browser

MeSH Browser

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

Cubby

Related

Resources

Order Documents

NLM Gateway

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Rev Chir Orthop Reparatrice Appar Mot
1998 Nov;84(8):743-51

CrossMark

Related Articles, Books,

LinkOut

[Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis.]

[Article in French]

Chapurlat R, Meunier PJ.

Service de Rhumatologie et de Pathologie Osseuse, Hopital Edouard Herriot, Lyon.

Paget's disease of bone, bone fibrous dysplasia and osteoporosis are characterized by abnormal bone remodeling, and frequently imply intervention of orthopedists. Recent significant medical therapeutics improvements have been obtained with the use of bisphosphonates. These drugs decrease bone remodeling. In Paget's disease, bisphosphonates relieve bone pain, allow lytic areas refilling and decrease complications risk with normal bone formation. In fibrous dysplasia, bone pain is alleviated, osteolytic areas are refilled and cortices are widened. In postmenopausal osteoporosis, bisphosphonates increase bone mineral density, and reduce very significantly the subsequent risk of vertebral, femoral and lower forearm fractures. Bisphosphonates are a breakthrough in Paget's disease of bone, fibrous dysplasia of bone and osteoporosis.

Publication Types:

- Review
- Review, Tutorial

PMID: 10192126 [PubMed - indexed for MEDLINE]